Minerva Neurosciences, Inc. (NERV): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of NERV were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Minerva Neurosciences
From the latest filingsOverall: more buying than selling. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns NERV
59 funds and institutions reported NERV shares worth $235M at the end of Q2 2026, about 98% of the company. The largest holder is Federated Hermes, Inc. with 10.8%.
Funds and institutions (13F) 98%Everyone else 2%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Federated Hermes, Inc. | 4.67M | 10.79% | $25.9M | -9% |
| Jupiter Topco LLC | 4.39M | 10.14% | $24.3M | New |
| Vivo Capital, LLC | 4.32M | 9.99% | $24M | No change |
| Balyasny Asset Management L.P. | 4.26M | 9.84% | $23.6M | No change |
| Logos Global Management LP | 3.29M | 7.60% | $18.3M | +2% |
| Farallon Capital Management, L.l.c. | 2.37M | 5.47% | $13.1M | No change |
| BlackRock, Inc. | 2.24M | 5.18% | $12.4M | +259% |
| Ally Bridge Group (NY) LLC | 2.18M | 5.03% | $12.1M | +31% |
| Foresite Capital Management VI LLC | 1.99M | 4.59% | $11M | -0% |
| Vanguard Capital Management LLC | 1.89M | 4.37% | $10.5M | +3% |
| Spruce Street Capital LP | 1.66M | 3.83% | $9.2M | No change |
| Trails Edge Capital Partners, LP | 1.42M | 3.28% | $7.9M | No change |
| Adage Capital Partners Gp, L.l.c. | 1.42M | 3.28% | $7.9M | No change |
| Seven Fleet Capital Management LP | 1.00M | 2.31% | $5.6M | +303% |
| Geode Capital Management, LLC | 974,236 | 2.25% | $5.4M | +188% |
| Dv Equities, LLC | 754,397 | 1.74% | $4.2M | New |
| Acuta Capital Partners, LLC | 709,500 | 1.64% | $3.9M | No change |
| Millennium Management LLC | 533,602 | 1.23% | $3M | -25% |
| State Street Corp | 424,915 | 0.98% | $2.4M | +654% |
| Vanguard Fiduciary Trust Co | 302,604 | 0.70% | $1.7M | +15% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No NERV insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
NERV short interest
Low short interest. 4.0% of NERV shares are sold short: about 1 share in 25. Over the last 12 reports the number of shares short went up 60%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.90M NERV shares were sold short, 4.0% of the shares outstanding, down 21.2% from the report before. At the average daily volume of 181,378 shares, buying them all back would take about 10.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.90M | 3.97% | -21% | 181,378 | 10.5 |
| Oct 15, 2026 | 2.41M | 5.04% | -1% | 129,747 | 18.6 |
| Sep 30, 2026 | 2.44M | 5.10% | +1% | 187,984 | 13.0 |
| Sep 15, 2026 | 2.42M | 5.07% | +15% | 120,275 | 20.1 |
| Aug 31, 2026 | 2.11M | 4.42% | +20% | 332,755 | 6.3 |
| Aug 14, 2026 | 1.76M | 3.68% | -28% | 149,367 | 11.8 |
| Jul 31, 2026 | 2.45M | 5.66% | +1% | 157,495 | 15.5 |
| Jul 15, 2026 | 2.42M | 5.59% | +27% | 193,281 | 12.5 |
| Jun 30, 2026 | 1.90M | 4.40% | +70% | 589,572 | 3.2 |
| Jun 15, 2026 | 1.12M | 2.58% | +14% | 105,486 | 10.6 |
| May 29, 2026 | 982,569 | 2.27% | -17% | 173,002 | 5.7 |
| May 15, 2026 | 1.19M | 2.74% | -11% | 110,616 | 10.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Minerva Neurosciences company events
Minerva Neurosciences filed 12 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 6, 2026.
- Nov 6, 2026ResultsReleased financial results. Filing
- Aug 12, 2026LeadershipThe Board of Directors of Minerva Neurosciences, Inc. appointed Anthony Aliquo, the Company’s Vice President, Controller, as Chief Accounting Officer and principal accounting officer of the Company, effective as of that date. Filing
- Aug 7, 2026ResultsReleased financial results. Filing
- Jun 4, 2026SharesChanged the rights of its shareholders. Filing
- May 27, 2026AgreementMinerva Neurosciences, Inc. entered into a Sales Agreement with Leerink Partners LLC with respect to an “at-the market” offering program, pursuant to which the Company may issue and sell, from time to time, shares of its common stock, par value $0.0001 per share. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Apr 6, 2026AnnouncementMinerva Neurosciences, Inc. today announced that the expected date for the Company’s 2026 annual meeting of stockholders is June 3, 2026, which is more than 30 days before the one-year anniversary of the Company’s 2025 annual meeting of stockholders. Filing
- Apr 2, 2026LeadershipMinerva Neurosciences, Inc., a Delaware corporation, Mind-NRG SARL, a wholly-owned subsidiary of the Company, and Geoffrey Race, President of the Company, entered into a settlement agreement, pursuant to which Mr. Race resigned from his role as President of the Company and as a Director of… Filing
- Mar 11, 2026ResultsReleased financial results. Filing
- Feb 3, 2026AnnouncementAt the KOL event, the Company will provide additional details regarding its proposed confirmatory Phase 3 trial of roluperidone for the treatment of negative symptoms in schizophrenia. Filing
- Dec 22, 2025LeadershipMinerva Neurosciences, Inc. held its 2025 Annual Meeting of Stockholders. Filing
- Nov 19, 2025LeadershipDirector Appointment As previously disclosed, on October 21, 2025, Minerva Neurosciences, Inc. entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company agreed to increase the size of its Board of Directors and appoint up to three (3) directors to… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Minerva Neurosciences financials
Famous investors that hold NERV
3 of the 50 well-known investors we track reported holding NERV in their latest 13F filing. The largest position is Israel Englander's, worth $4.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 1.26M | $4.2M | 0.0% | +137% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 42,000 | $141K | 0.0% | -43% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 23,385 | $78.3K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named NERV in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 10.0% |
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 10.0% |
| Nov 13, 2026 | Coastlands Capital LP | 13G/A | 10.0% |
| Nov 13, 2026 | Coastlands Capital LP | 13G/A | 10.0% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.1% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.1% |
Questions about Minerva Neurosciences, Inc. (NERV) stock
Who owns the most NERV stock?
The largest reported owner of Minerva Neurosciences, Inc. (NERV) is Federated Hermes, Inc., with 10.8% of the company. In total, 59 funds and institutions reported holding NERV at the end of Q2 2026, together about 98% of the shares. See the largest owners.
Are NERV insiders buying or selling?
No NERV insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in NERV?
As of Oct 30, 2026, 1.90M NERV shares were sold short, 4.0% of the shares outstanding, down 21.2% from the report before. At the average daily volume of 181,378 shares, buying them all back would take about 10.5 trading days (days to cover). See the history.
Which famous investors hold NERV?
3 of the 50 well-known investors we track reported NERV in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $4.2M. See all holders.
Executive pay
Minerva Neurosciences's chief executive was paid a total of $9.4M for the year ended Dec 31, 2025, up 673% from $1.2M the year before. In the last 12 months, Minerva Neurosciences's executives and directors bought no stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.